:

Yong Liu1, Hui Liu2, Queqiao Bian1

  • 1Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Department of Dermatology and STD, The Third Central Hospital of Tianjin, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.

Frontiers in medicine
|October 10, 2024
PubMed
概括

陈列素 (HMGCR抑制剂) 可能降低非黑色素瘤皮肤癌和牛皮风险. PCSK9抑制剂 (alirocumab) 也可以降低牛皮的风险,这表明对皮肤疾病的潜在益处.